In HCC, a decreased MAP9 mediated by its promoter hypermethylation had been measured, and MAP9 downregulation or promoter hypermethylation was related to recurrence and poor survival [6, 8]. This evidence concerns the gene MAP9 and hepatocellular carcinoma.